IceCure Medical (ICCM)
Liquid-nitrogen cryoablation systems and disposable probes for minimally invasive tumor treatment.
Something off on this page? Send us feedback.
Liquid-nitrogen cryoablation systems and disposable probes treat targeted tumor tissue through a minimally invasive local procedure. Revenue combines console sales or placements with recurring disposable use, while commercialization relies on clinical evidence, regulatory authorization, and direct and distributor channels.
Designs, develops, manufactures and markets liquid-nitrogen cryoablation systems that guide a needle-like probe into benign or malignant tumors, freezing targeted tissue with a surrounding ice ball. ProSense is the lead single-probe platform; IceSense3 is the earlier commercial system, while XSense is FDA-cleared for existing ProSense-cleared indications and MSense remains in development.
Earns product revenue from console sales or placements, proprietary disposable CryoProbes, and related services. Hospitals, interventional-radiology centers, ambulatory facilities and private clinics are customers. Products reach markets directly and through distributors, with the largest reported revenue bucket including Europe and other territories.
FDA authorization for ProSense covers local treatment for a defined low-risk breast-cancer population in the United States rather than general replacement for breast surgery. The authorization carries a postmarket clinical-validation study requirement; non-U.S. commercialization also depends materially on distributor relationships.
Company facts
Categories
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior target | Target |
|---|---|---|---|---|
| May 4, 2026 | Industrial Alliance Securities | Target | $5.75 | $1 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $12.0M · Total debt $90.0K · Total assets $17.7M · Shareholders' equity $11.9M
- Revenue
- $907.0K
- Operating income
- $4.4M
- Net income
- −$4.5M
No dividends on record.
| Institutions18 holders · as of Mar 31, 2026 | 111.09% | 108.3K ADS | |
| Insiders10 holders · as of Aug 17, 2026 | 29.14% | 28.4K ADS | |
| Adds to | 140.23% |
97.5K ADS (1 ADS = 25 ordinary shares) as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (97.5K in the company's Sep 3, 2026 report, 2.25M elsewhere); stakes use the report.
These groups come from separate filings that can overlap, so they add to 140.23%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Armistice Capital, LLCInstitution | 92.72% | 2.71M ADS | 13Fas of Mar 31, 2026 |
Meir PelegInsiderofficer: Chief Financial Officer | 7.99% | 194,816 ordinary | Form 4filed Aug 17, 2026 ↗ |
Shay LevavInsiderofficer: Chief Operating Officer | 6.00% | 146,303 ordinary | Form 4filed Aug 17, 2026 ↗ |
Shad GoodInsiderofficer: VP, Sales for North America | 5.61% | 136,698 ordinary | Form 4filed Aug 17, 2026 ↗ |
UBS Group AGInstitution | 5.27% | 154,198 ADS | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- Boston Scientific
Direct multi-probe cryoablation rival in interventional oncology.
- Medtronic
Microwave ablation alternative for nonresectable liver tumors.
- AngioDynamics
Nonthermal focal-ablation alternative across solid-tumor care.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| IceCure Medical | $2.28 | +1.02% | $5.1M | — | — | 1.3 | +72.8% |
| Boston Scientific | $48.42 | +0.09% | $71.90B | 19.7 | 14.6 | 3.4 | +7.5% |
| Medtronic | $92.40 | +0.22% | $118.00B | 22.7 | 15.3 | 3.1 | +13.7% |
| AngioDynamics | $15.63 | −1.45% | $645.6M | — | — | 2.0 | +8.1% |
| Median | 21.2 | 15.0 | 3.1 | +8.1% |